David W. Ussery
Professor of Genetics
Also affiliated: Kunming University of Science and Technology (2018); Universitat de Miguel Hernández d'Elx (2012); Oklahoma State University (2026); Oak Ridge National Laboratory (2011–2017); Siriraj Hospital (2018); Norwegian Computing Center (2007); University of New Mexico (1984); Texas A&M University System (1992–1993); University of Oslo (2007–2011); Mahidol University (2018); University of Arkansas Medical Center (2017–2021); John Radcliffe Hospital (1994–1997); Moffitt Cancer Center (1994); University of Oxford (1994–1997); Molecular Microbiology and Genomics Consultants (Germany) (2017–2018); University of Applied Management Studies (2025); Oklahoma State University Oklahoma City (2025); Joint Institute for Computational Sciences (2014–2015); Anstalt für Verbrennungskraftmaschinen List (Austria) (2019); University of Cincinnati (1991); University of Tennessee at Knoxville (2014–2015); Texas A&M University (1996); University of Cincinnati Medical Center (1991); Technical University of Denmark (1999–2016)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
David W. Ussery studies the bioinformatic analysis of bacterial genomes, a field he has engaged with since 1995. His research has focused on comparative genomics, including the investigation of Escherichia coli phylogroups and the genomic surveillance of pathogens like SARS-CoV-2 and Monkeypox virus. He led the Arkansas Center for Genomic Epidemiology and Medicine from 2016 to 2025, during which his group sequenced the first COVID-19 Omicron variant in Arkansas and developed methods for wastewater pathogen monitoring.
Ussery has experience teaching graduate courses in bioinformatics and has conducted numerous comparative genomics workshops globally. His scholarly work includes over 360 publications, with a significant number of highly cited papers, and an h-index of 62. He has established collaborative projects with researchers in several countries and maintains active lab operations. His work is supported by collaborations with colleagues at the University of Arkansas for Medical Sciences and the University of Arkansas at Little Rock.
His research interests also extend to areas such as the origins of mutational signatures in cancer and DNA structural features of MHC locus sequences. Ussery's contributions have been recognized with designations such as an ARA Academy member and a highly-impacted researcher.
Metrics
- h-index: 62
- Publications: 361
- Citations: 26,620
Selected Publications
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
A Tracts of Homozygosity Approach Identifies Methylation-Regulated <i>CSMD1</i> Expression Targets in Non–Small Cell Lung Cancers Related to Smoking Behavior (2025)
-
Using machine learning to predict the severity of salmonella infection (2025)
-
Abstract 1923: A tract of homozygosity analysis reveals methylation-driven <i>CSMD1</i> expression in non-small cell lung cancers (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Investigating the origins of the mutational signatures in cancer (2025)
-
C.S. Lewis Philosopher — Who Changed My Life. Notes on the Margins of The Magician's Twin (2024)
-
Review 1: "Emergence of Transmissible SARS-CoV-2 Variants with Decreased Sensitivity to Antivirals in Immunocompromised Patients with Persistent Infections" (2024)
-
Reviews of "Emergence of Transmissible SARS-CoV-2 Variants with Decreased Sensitivity to Antivirals in Immunocompromised Patients with Persistent Infections" (2024)
-
DNA structural features and variability of complete MHC locus sequences (2024)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Genomic surveillance of SARS-CoV-2 using long-range PCR primers (2024)
-
Review of: "Can the definitions of SARS-Cov-2 and Covid-19 stand up to epistemological scrutiny?" (2023)
-
Review of: "Evolution of new variants of SARS-CoV-2 during the pandemic: mutation-limited or selection-limited?" (2023)
-
Genomic Surveillance of SARS-CoV-2 Using Long-Range PCR Primers (2023)
ARA Academy 2016 ARA Scholar
Collaboration Network
Top Collaborators
- Two SARS-CoV-2 Genome Sequences of Isolates from Rural U.S. Patients Harboring the D614G Mutation, Obtained Using Nanopore Sequencing
- Investigating the origins of the mutational signatures in cancer
- Is amplification bias consequential in transposon sequencing (TnSeq) assays? A case study with a Staphylococcus aureus TnSeq library subjected to PCR-based and amplification-free enrichment methods
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Showing 5 of 7 shared publications
- Mash-based analyses of Escherichia coli genomes reveal 14 distinct phylogroups
- The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2
- Comparison of Monkeypox virus genomes from the 2017 Nigeria outbreak and the 2022 outbreak
- Two SARS-CoV-2 Genome Sequences of Isolates from Rural U.S. Patients Harboring the D614G Mutation, Obtained Using Nanopore Sequencing
- DNA structural features and variability of complete MHC locus sequences
- Mash-based analyses of Escherichia coli genomes reveal 14 distinct phylogroups
- The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2
- Comparison of Monkeypox virus genomes from the 2017 Nigeria outbreak and the 2022 outbreak
- DNA structural features and variability of complete MHC locus sequences
- Big data in genomic research for big questions with examples from covid-19 and other zoonoses
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- Mash-based analyses of Escherichia coli genomes reveal 14 distinct phylogroups
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Genomic surveillance of SARS-CoV-2 using long-range PCR primers
- Genomic Surveillance of SARS-CoV-2 Using Long-Range PCR Primers
- Severe Acute Respiratory Syndrome Coronavirus-2 Lambda Variant Collected from a Child from Arkansas and Sequenced
- Genomic surveillance of SARS-CoV-2 using long-range PCR primers
- Genomic Surveillance of SARS-CoV-2 Using Long-Range PCR Primers
- Severe Acute Respiratory Syndrome Coronavirus-2 Lambda Variant Collected from a Child from Arkansas and Sequenced
- Genomic surveillance of SARS-CoV-2 using long-range PCR primers
- Genomic Surveillance of SARS-CoV-2 Using Long-Range PCR Primers
- Severe Acute Respiratory Syndrome Coronavirus-2 Lambda Variant Collected from a Child from Arkansas and Sequenced
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Similar Researchers
Based on overlapping research topics